J. Cavanagh

Persistent physical symptoms: definition, genesis, and management

Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis

Guided self-help for functional (psychogenic) symptoms

Which neurological diseases are most likely to be associated with “symptoms unexplained by organic disease”